The new European regulation on pediatric medicines: regulatory perspective.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. A point-of-care pharmacokinetic/pharmacodynamic trial in critically ill children: Study design and feasibility.Contemporary clinical trials communications · 2023
   Article
2. Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.Clinical pharmacokinetics · 2019
   Review
3. Two decades of off-label prescribing in children: a literature review.World journal of pediatrics : WJP · 2018
   Review
4. Design and conduct of early phase drug studies in children: challenges and opportunities.British journal of clinical pharmacology · 2016
   Review
5. Reported paediatric adverse drug reactions in the UK 2000-2009.British journal of clinical pharmacology · 2012
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as